Citius Pharmaceuticals Inc (CTXR)

Currency in USD
0.5172
-0.0016(-0.31%)
Real-time Data·
CTXR is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.50000.5300
52 wk Range
0.36991.5399
Key Statistics
Prev. Close
0.5188
Open
0.53
Day's Range
0.5-0.53
52 wk Range
0.3699-1.5399
Volume
31.99K
Average Volume (3m)
318.31K
1-Year Change
-51.6636%
Book Value / Share
2.43
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CTXR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
4.0000
Upside
+673.40%
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week

Citius Pharmaceuticals Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Strong Buy

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 4.0000
(+673.40% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy4.00+673.40%-MaintainAug 19, 2026
H.C. Wainwright
Buy4.00+673.40%-New CoverageMay 18, 2026

Earnings

Latest Release
Aug 17, 2026
EPS / Forecast
-0.34 / 0.03
Revenue / Forecast
1.5M / 12.52M
EPS Revisions
Last 90 days

CTXR Income Statement

Compare CTXR to Peers and Sector

Metrics to compare
CTXR
Peers
Sector
Relationship
P/E Ratio
−0.3x−0.9x−0.2x
PEG Ratio
−0.01−0.170.00
Price/Book
0.2x11.5x2.6x
Price / LTM Sales
2.0x2.0x2.7x
Upside (Analyst Target)
-97.8%68.5%
Fair Value Upside
Unlock20.6%11.5%Unlock

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company’s late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
636.50K2.32%335.82K
Other Institutional Investors
790.22K2.88%416.92K
Public Companies & Retail Investors
26.03M94.80%13.73M
Total
27.45M100.00%14.48M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Vanguard Capital Management, LLC1.00%275,119145
Vanguard Index Funds - Vanguard Extended Market ETF0.96%264,672140

People Also Watch

2.185
AHT
-1.58%
2.6700
KUST
-4.30%
48.54
CE
-0.25%
0.6099
CRIS
+12.57%
2.8896
NCPL
+21.92%

FAQ

What Is the Citius Pharmaceuticals (CTXR) Stock Price Today?

The Citius Pharmaceuticals stock price today is 0.5172 USD.

What Stock Exchange Does Citius Pharmaceuticals Trade On?

Citius Pharmaceuticals is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Citius Pharmaceuticals?

The stock symbol for Citius Pharmaceuticals is "CTXR."

What Is the Citius Pharmaceuticals Market Cap?

As of today, Citius Pharmaceuticals market cap is 14.2000M USD.

What Is Citius Pharmaceuticals's Earnings Per Share (TTM)?

The Citius Pharmaceuticals EPS (TTM) is -2.12.

When Is the Next Citius Pharmaceuticals Earnings Date?

Citius Pharmaceuticals will release its next earnings report on Dec 17, 2026.

From a Technical Analysis Perspective, Is CTXR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Citius Pharmaceuticals Stock Split?

Citius Pharmaceuticals has split 3 times.

How Many Employees Does Citius Pharmaceuticals Have?

Citius Pharmaceuticals has 23 employees.

What is the current trading status of Citius Pharmaceuticals (CTXR)?

As of Nov 18, 2026, Citius Pharmaceuticals (CTXR) is trading at a price of 0.5172 USD, with a previous close of 0.5188 USD. The stock has fluctuated within a day range of 0.5000 USD to 0.5300 USD, while its 52-week range spans from 0.3699 USD to 1.5399 USD.

What Is Citius Pharmaceuticals (CTXR) Price Target According to Analysts?

The average 12-month price target for Citius Pharmaceuticals is 4.0000 USD, with a high estimate of 4 USD and a low estimate of 4 USD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +673.40% Upside potential.

What Is the CTXR Premarket Price?

CTXR's last pre-market stock price is 0.5400 USD. The pre-market share volume is 840.0000, and the stock has decreased by 0.0212, or 4.0900%.

What Is the CTXR After Hours Price?

CTXR's last after hours stock price is 0.5115 USD, the stock has decreased by -0.0073, or -1.4100%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.